tiprankstipranks
Advertisement
Advertisement
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
PremiumCompany AnnouncementsHigh-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
1M ago
Vistagen Therapeutics Balances Progress and Uncertainty
Premium
Company Announcements
Vistagen Therapeutics Balances Progress and Uncertainty
1M ago
Vistagen reports Q3 EPS (45c), consensus (49c)
Premium
The Fly
Vistagen reports Q3 EPS (45c), consensus (49c)
1M ago
VistaGen updates corporate presentation highlighting neuroscience pipeline
PremiumCompany AnnouncementsVistaGen updates corporate presentation highlighting neuroscience pipeline
3M ago
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
Premium
Company Announcements
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
3M ago
Vistagen downgraded to Hold from Buy at Jefferies
Premium
The Fly
Vistagen downgraded to Hold from Buy at Jefferies
3M ago
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
PremiumThe FlyVistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
3M ago
Vistagen downgraded to Hold from Buy at Stifel
Premium
The Fly
Vistagen downgraded to Hold from Buy at Stifel
3M ago
Vistagen downgraded to Neutral from Buy at Lucid Capital
Premium
The Fly
Vistagen downgraded to Neutral from Buy at Lucid Capital
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100